Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. - Wikidata - awgldk - TriplyDB

Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia.

Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia.

http://www.wikidata.org/entity/Q42453965

about

Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke Aging and the neurovascular unit Inhibition of MMP-2 but not MMP-9 influences inner ear spiral ganglion neurons in vitro.Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator Hemostasis and alterations of the central nervous system Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?Relationship of neurovascular elements to neuron injury during ischemia.Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement.Infrared optical imaging of matrix metalloproteinases (MMPs) up regulation following ischemia reperfusion is ameliorated by hypothermia.Hypoxia-ischemia or excitotoxin-induced tissue plasminogen activator- dependent gelatinase activation in mice neonate brain microvessels.Inward remodeling of resistance arteries requires reactive oxygen species-dependent activation of matrix metalloproteinases.Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence.Bystander Effect Fuels Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells to Quickly Attenuate Early Stage Neurological Deficits After Stroke.Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation.The neurovascular unit, matrix proteases, and innate inflammation.Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke.Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia.Immunologic privilege in the central nervous system and the blood-brain barrier.The rapid decrease in astrocyte-associated dystroglycan expression by focal cerebral ischemia is protease-dependent.Virchow's triad: the vascular basis of cerebral injury Ultrastructural and temporal changes of the microvascular basement membrane and astrocyte interface following focal cerebral ischemia.Inflammation and the neurovascular unit in the setting of focal cerebral ischemia.The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability.2-Chloroethanol Induced Upregulation of Matrix Metalloproteinase-2 in Primary Cultured Rat Astrocytes Via MAPK Signal Pathways.The neurovascular unit in the setting of stroke.Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury.Matrix metalloproteinases and small artery remodeling.Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury.Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders.Neuropathic pain: role of inflammation, immune response, and ion channel activity in central injury mechanisms.Spinal cord injury induced neuropathic pain: Molecular targets and therapeutic approaches.Matrix metalloproteinases as therapeutic targets for stroke.Matrix metalloproteinases in cerebral ischemia.New approach to identify ischemic stroke patients at risk to develop hemorrhagic transformation.Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles.The expression of matrix metalloproteinase-13 is increased in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model.Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB.Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and in vivo models of stroke.Involvement of matrix metalloproteinases-2 and -9 in the formation of a lacuna-like cerebral cavity.Post-ischemic treatment with azithromycin protects ganglion cells against retinal ischemia/reperfusion injury in the rat.

P2860

Q26766038-5AE3653C-AF18-484A-88E0-5207C3331F6D Q27026843-00D7D538-7233-4CB1-B3A7-686582B060F6 Q30414848-F380CB74-30AA-4AB8-B398-9C75C47E04B5 Q33823616-A23B92F0-DBD2-4599-86A0-4C5B47C93B63 Q33842161-C23B30E9-521D-47C3-B874-8DC596827321 Q34018715-E3E28916-1E7E-4200-9775-BF05EE007248 Q34038281-40D2BCF4-99D7-43B6-89E7-9961F790A5C1 Q34170971-04606FD2-9357-46FB-ABF1-E8B505C525DC Q34319977-48B857B4-2872-41E9-A593-D95516414F82 Q34937315-B2386A21-563B-4E29-9176-26A9E3322995 Q35056901-2D4C83B3-C30D-4731-8181-098019B51D3D Q35240865-561A5967-48C1-4524-B91C-6B81920B6AC5 Q35777502-2E7AE7D2-76EF-4BBF-9D4E-B653353F0D39 Q35939162-C848C5E5-221F-4A3E-96EE-1D69F9CA98DC Q35990775-47D8AEE7-8500-47D3-81B3-BB387B5B858E Q36351793-BB3145B8-DB40-4C38-970E-C098C993FCAD Q36644315-C7FE866D-13E4-4087-A582-141ACBCE6661 Q36684162-C62F5A2B-881E-44EB-A163-4D7C4666AC67 Q36986793-2DFFC1E4-79CE-4F28-AFD2-505D16A7DF89 Q37223437-9313BF6C-AC18-48AC-B8E1-37660F3A85C1 Q37264260-6D7DCC56-58B8-4A60-A44B-8D63E367F571 Q37281874-D0943908-F547-4794-A10F-EC9123586A15 Q37286882-23BB3068-4BB6-4BF2-B71F-5ED0A666075D Q37553275-21FA5DBC-CBD6-440D-8E49-8E067A4787D9 Q37696584-E4E3827D-D051-48A5-91B9-A2AE5795E750 Q37800133-516CC16D-A4C9-4FCB-A23E-84CAE4B1B8DA Q37962503-BEA96715-8E2D-4D68-AC88-C66841E63477 Q38030379-1043F5C3-9FBF-43F5-B0A1-8901314DFC6E Q38151704-AA0611D0-AE9B-412B-BAB0-44E2789F5B80 Q38247950-A676DDED-AEFC-46E4-B233-98155899A180 Q38318458-7C91A8AF-55C4-4910-980D-C10FA03E9536 Q38444452-30C978BE-DD5C-4DF5-9ABB-7BB2AA448BDE Q40028510-28447095-FF62-4D00-84A1-450B5D63B7AC Q41362038-E195CB4D-4824-4BCE-AE12-950430EDB3A1 Q41654070-498C9D54-F3DA-4209-A122-30BABF089DE4 Q43799003-95498EFF-90EB-4343-9AF6-9A45F3E61027 Q46044860-9E87B1B9-A9C7-4CA5-BBCC-D5CC3498E59F Q46110252-48253EA7-0BE6-47FF-B806-3EF12303F3A2 Q46150981-F6F0479B-5C36-4637-8C41-6DF56779CDFF Q47119067-531DBED6-C38A-46C7-8E3E-639420AE75A0

P2860

Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia.

http://www.wikidata.org/entity/Q42453965

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Activation systems for latent ...... after focal cerebral ischemia.

@en

Activation systems for latent ...... after focal cerebral ischemia.

@nl

type

label

Activation systems for latent ...... after focal cerebral ischemia.

@en

Activation systems for latent ...... after focal cerebral ischemia.

@nl

prefLabel

Activation systems for latent ...... after focal cerebral ischemia.

@en

Activation systems for latent ...... after focal cerebral ischemia.

@nl

P1433

Q42453965-D32B702D-0C03-430E-86BE-0A7F439DAB17

P1476

Q42453965-B471C01A-6C98-4517-99EF-9BD6DB9FC457

P2093

Q42453965-13F5A3F0-D44B-4B8A-8A89-08F5158B4075

Q42453965-504A4D8F-8048-4C68-8A6D-B4A938148541

Q42453965-790733EC-565E-464E-97DA-252BC0AE9B10

Q42453965-80E7A722-0CAA-4AAF-93F8-1F260576F8F4

Q42453965-9B02120E-2441-496E-926C-270239940DA1

Q42453965-B267EC81-D56C-44D0-9C65-7DAC42748156

P2860

Q42453965-07D0C937-F0F6-42E6-8277-EA79293267FF

Q42453965-0B6ABB08-5BD3-434C-BB5D-9EF1C472E8DE

Q42453965-0E2433C2-D110-49F9-A955-2781524A5DC4

Q42453965-0E4F3EB5-77AA-44EC-8C0E-D167925027FE

Q42453965-123E049F-A1A6-4EFA-BC6A-08ACA258DADA

Q42453965-17862AF0-2FC3-4908-8EC8-6A633EA1BEA5

Q42453965-259F6FC1-E2E7-47D0-8BDC-8D9C445FD24F

Q42453965-2793BDD2-FC6E-41A1-9817-63BE63CFE205

Q42453965-2E944B30-BF2F-43F9-9C62-A2F087F6CB3A

Q42453965-33374CDB-9A35-4CE9-A33C-DEEDAE8BB068

P2888

Q42453965-C00799EA-BA22-487E-A5DF-556C154A74ED

P304

Q42453965-9805B60B-7FC1-4BAA-94D6-EA4170E719E2

P31

Q42453965-7BD9ECC9-64DB-40BA-A8D7-62BCAB6AAABE

P356

Q42453965-38693051-2014-4FD0-8606-BA545493AA98

P433

Q42453965-7FA36A01-E61B-43A6-BE9D-16B336FD2562

P478

Q42453965-8CA90900-4D61-41A1-8052-7788D0F1D59F

P50

Q42453965-A783CF1C-6A19-447C-A6D0-BCCBDB9EFB22

P577

Q42453965-08060CAB-A2B9-4CD4-98C1-014D30EDDC6B

P6179

Q42453965-9050D726-5624-4440-B7AB-68AA81C07075

P698

Q42453965-500859A3-F1ED-45AE-9264-0C63B08E6FE8

P921

Q42453965-4790D346-D773-4517-879F-339AB0324C09

P356

01.WCB.0000091765.61714.30

P1433

Journal of Cerebral Blood Flow & Metabolism

P1476

Activation systems for latent ...... after focal cerebral ischemia

@en

P2093

Andrew P Mazar

http://www.w3.org/2001/XMLSchema#string

Dae-Il Chang

http://www.w3.org/2001/XMLSchema#string

Gregory J del Zoppo

http://www.w3.org/2001/XMLSchema#string

Jacinta Lucero

http://www.w3.org/2001/XMLSchema#string

Naohisa Hosomi

http://www.w3.org/2001/XMLSchema#string

Takeo Abumiya

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family

A matrix metalloproteinase expressed on the surface of invasive tumour cells

Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes

Disruption of epithelial cell-matrix interactions induces apoptosis

cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment

Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia

Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain

Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate

Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease

Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor

P2888

01.wcb.0000091765.61714.30

P304

1408-1419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.WCB.0000091765.61714.30

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1017723260

http://www.w3.org/2001/XMLSchema#string

P698

14663336

http://www.w3.org/2001/XMLSchema#string

P921

cerebral infarction